The strategies currently used to monitor concentrations of cyclosporine (CsA) in trans- planted patients include whole blood trough (C0), total or abbreviated area under the curve (AUC) concentration and population pharmacokinetic approaches. Recently, a single blood concentration measurement at 2 hours (C2) after CsA administration has been shown to be helpful to predict clinical effects during the first weeks after transplan- tation of liver and kidney grafts. However, this approach has raised multiple questions about pharmacokinetic variability, analytical methods, and organizational requirements. From a pharmacokinetic point of view, the variability of CsA blood concentrations may relate to circadian variations. The present study sought...
The clinical management of cyclosporine has evolved greatly during the last decade thanks to the use...
Although a generalized consensus has been reached for therapeutic drug monitoring of cyclosporine mi...
The factors affecting CyA dosing and kinetics in LT patients are complex, and have been thoroughly i...
With the recent focus of monitoring cyclosporine (CsA) therapy using measures of CsA absorption, it ...
The correct use of immunosuppressive drugs has a considerable influence on the prognosis of patients...
Earlier experimental studies have shown that the cyclosporin immunosuppressive effect (CsA) can be m...
Background: Cyclosporin (CsA) dose selection is complicated by significant pharmacokinetic variabili...
Currently, routine monitoring of cyclosporine in patients undergoing allogeneic stem cell transplant...
This study analyzed early changes in trough blood cyclosporine concentrations and cyclosporine expos...
Blood concentrations of cyclosporine A (CsA) >or=800 microg/l measured 2 h post-dosing, the C2 conce...
Abstract Background. Therapeutic monitoring (TM) of cyclosporine (CyA), by measuring drug concentrat...
After using C0-monitoring as the tool for therapeutic drug monitoring of cyclosporine for many years...
AbstractCyclosporine-based immunosuppression is common after allogeneic hematopoietic stem cell tran...
Immunosuppression has been one of the great challenges in pediatric recipients of kidney allografts....
Objective: Absorption profiling of cyclosporine is a current concept of drug monitoring. A single bl...
The clinical management of cyclosporine has evolved greatly during the last decade thanks to the use...
Although a generalized consensus has been reached for therapeutic drug monitoring of cyclosporine mi...
The factors affecting CyA dosing and kinetics in LT patients are complex, and have been thoroughly i...
With the recent focus of monitoring cyclosporine (CsA) therapy using measures of CsA absorption, it ...
The correct use of immunosuppressive drugs has a considerable influence on the prognosis of patients...
Earlier experimental studies have shown that the cyclosporin immunosuppressive effect (CsA) can be m...
Background: Cyclosporin (CsA) dose selection is complicated by significant pharmacokinetic variabili...
Currently, routine monitoring of cyclosporine in patients undergoing allogeneic stem cell transplant...
This study analyzed early changes in trough blood cyclosporine concentrations and cyclosporine expos...
Blood concentrations of cyclosporine A (CsA) >or=800 microg/l measured 2 h post-dosing, the C2 conce...
Abstract Background. Therapeutic monitoring (TM) of cyclosporine (CyA), by measuring drug concentrat...
After using C0-monitoring as the tool for therapeutic drug monitoring of cyclosporine for many years...
AbstractCyclosporine-based immunosuppression is common after allogeneic hematopoietic stem cell tran...
Immunosuppression has been one of the great challenges in pediatric recipients of kidney allografts....
Objective: Absorption profiling of cyclosporine is a current concept of drug monitoring. A single bl...
The clinical management of cyclosporine has evolved greatly during the last decade thanks to the use...
Although a generalized consensus has been reached for therapeutic drug monitoring of cyclosporine mi...
The factors affecting CyA dosing and kinetics in LT patients are complex, and have been thoroughly i...